<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38169007</PMID><DateCompleted><Year>2024</Year><Month>03</Month><Day>20</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1076</ISSN><JournalIssue CitedMedium="Internet"><Volume>183</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Mar</Month></PubDate></JournalIssue><Title>European journal of pediatrics</Title><ISOAbbreviation>Eur J Pediatr</ISOAbbreviation></Journal><ArticleTitle>Vaccination against COVID-19 - risks and benefits in children.</ArticleTitle><Pagination><StartPage>1107</StartPage><EndPage>1112</EndPage><MedlinePgn>1107-1112</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00431-023-05380-8</ELocationID><Abstract><AbstractText>Countries in Europe and around the world have taken varying approaches to their policies on COVID-19 vaccination for children. The low risk of severe illness from COVID-19 means that even small risks from vaccination warrant careful consideration. Vaccination appears to result in a decreased risk of severe illness including the paediatric multi-system inflammatory syndrome known to be associated with COVID-19. These risks have already decreased significantly with the emergence of the Omicron variant and its subvariants, and due to widespread population immunity through previous infection. There is a relatively high risk of myocarditis following second doses of mRNA vaccines in adolescent males, although the general course of this condition appears mild. &#xa0; Conclusion: COVID-19 vaccination only provides a transient reduction in transmission. Currently, insufficient evidence exists to determine the impact of vaccination on post-acute COVID syndromes in children, which are uncommon. What is Known: &#x2022; Vaccines against COVID-19 have significantly reduced morbidity and mortality around the world. &#x2022; Whilst countries have universally recommended vaccines for adults and continue to recommend them for vulnerable populations, there has been more variability in recommendations for children. What is New: &#x2022; In the setting of near universal existing immunity from infection, the majority of the initial benefit in protecting against severe illness has been eroded. &#x2022; The risks of myocarditis following mRNA vaccination for children is low, but an important consideration given the modest benefits.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Munro</LastName><ForeName>Alasdair P S</ForeName><Initials>APS</Initials><AffiliationInfo><Affiliation>NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Christine E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faust</LastName><ForeName>Saul N</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK. s.faust@soton.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK. s.faust@soton.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>01</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur J Pediatr</MedlineTA><NlmUniqueID>7603873</NlmUniqueID><ISSNLinking>0340-6199</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000705967">pediatric multisystem inflammatory disease, COVID-19 related</SupplMeshName><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009205" MajorTopicYN="Y">Myocarditis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018746" MajorTopicYN="Y">Systemic Inflammatory Response Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Immunisation</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">MIS-C</Keyword><Keyword MajorTopicYN="N">PIMS-TS</Keyword><Keyword MajorTopicYN="N">Vaccination</Keyword></KeywordList><CoiStatement>AM, CJ and SF have their salaries paid in part by the NIHR Southampton Clinical Research Facility and Biomedical Research Centre.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>12</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>20</Day><Hour>6</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>1</Month><Day>4</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>1</Month><Day>3</Day><Hour>11</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38169007</ArticleId><ArticleId IdType="pmc">PMC10950962</ArticleId><ArticleId IdType="doi">10.1007/s00431-023-05380-8</ArticleId><ArticleId IdType="pii">10.1007/s00431-023-05380-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis. 2022;22(9):1293&#x2013;1302. doi: 10.1016/S1473-3099(22)00320-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00320-6</ArticleId><ArticleId IdType="pmc">PMC9225255</ArticleId><ArticleId IdType="pubmed">35753318</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilde H, Tomlinson C, Mateen BA, Selby D, Kanthimathinathan HK, Ramnarayan P, et al. Hospital admissions linked to SARS-CoV-2 infection in children and adolescents: cohort study of 3.2 million first ascertained infections in England. BMJ. 2023;382:073639.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10318942</ArticleId><ArticleId IdType="pubmed">37407076</ArticleId></ArticleIdList></Reference><Reference><Citation>Otero S, Miller ES, Sunderraj A, Shanes ED, Sakowicz A, Goldstein JA, et al. Maternal antibody response and transplacental transfer following severe acute respiratory syndrome coronavirus 2 infection or vaccination in pregnancy. Clin Infect Dis. 2022;76(2):220&#x2013;228. doi: 10.1093/cid/ciac793.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac793</ArticleId><ArticleId IdType="pmc">PMC10202423</ArticleId><ArticleId IdType="pubmed">36348510</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan SHX, Cook AR, Heng D, Ong B, Lye DC, Tan KB. Effectiveness of BNT162b2 vaccine against Omicron in children 5 to 11 years of age. N Engl J Med. 2022;387(6):525&#x2013;532. doi: 10.1056/NEJMoa2203209.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2203209</ArticleId><ArticleId IdType="pmc">PMC9342421</ArticleId><ArticleId IdType="pubmed">35857701</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacco C, Del Manso M, Mateo-Urdiales A, Rota MC, Petrone D, Riccardo F, et al. Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5&#x2013;11 years in Italy: a retrospective analysis of January&#x2013;April, 2022. The Lancet. 2022;400(10346):97&#x2013;103. doi: 10.1016/S0140-6736(22)01185-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01185-0</ArticleId><ArticleId IdType="pmc">PMC9246475</ArticleId><ArticleId IdType="pubmed">35780801</ArticleId></ArticleIdList></Reference><Reference><Citation>Piechotta V, Siemens W, Thielemann I, Toews M, Koch J, Vygen-Bonnet S, et al. Safety and effectiveness of vaccines against COVID-19 in children aged 5&#x2013;11 years: a systematic review and meta-analysis. The Lancet Child &amp; Adolescent Health. 2023;7(6):379&#x2013;391. doi: 10.1016/S2352-4642(23)00078-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-4642(23)00078-0</ArticleId><ArticleId IdType="pmc">PMC10112865</ArticleId><ArticleId IdType="pubmed">37084750</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul Birrell JB, Edwin van Leeuwen, MRC Biostatistics Unit COVID-19 Working Group, Daniela De Angelis. COVID-19: nowcast and forecast: MRC Biostatistics Unit COVID-19 Working Group; 2022 [Available from: https://joshuablake.github.io/public-RTM-reports/iframe.html.</Citation></Reference><Reference><Citation>Zsigmond B, Breathnach AS, Mensah A, Ladhani SN. Very low rates of severe COVID-19 in children hospitalised with confirmed SARS-CoV-2 infection in London. England J Infect. 2022;85(1):90&#x2013;122. doi: 10.1016/j.jinf.2022.04.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2022.04.020</ArticleId><ArticleId IdType="pmc">PMC9645775</ArticleId><ArticleId IdType="pubmed">35417737</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardelid P, Favarato G, Wijlaars L, Fenton L, McMenamin J, Clemens T, et al. SARS-CoV-2 tests, confirmed infections and COVID-19-related hospital admissions in children and young people: birth cohort study. BMJ Paediatrics Open. 2022;6(1):e001545. doi: 10.1136/bmjpo-2022-001545.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjpo-2022-001545</ArticleId><ArticleId IdType="pmc">PMC9437731</ArticleId><ArticleId IdType="pubmed">36053647</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertran M, Amin-Chowdhury Z, Davies HG, Allen H, Clare T, Davison C, et al. COVID-19 deaths in children and young people in England, March 2020 to December 2021: an active prospective national surveillance study. PLoS Med. 2022;19(11):e1004118. doi: 10.1371/journal.pmed.1004118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1004118</ArticleId><ArticleId IdType="pmc">PMC9642873</ArticleId><ArticleId IdType="pubmed">36346784</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker JL, Grint DJ, Strongman H, Eggo RM, Peppa M, Minassian C, et al. UK prevalence of underlying conditions which increase the risk of severe COVID-19 disease: a point prevalence study using electronic health records. BMC Public Health. 2021;21(1):484. doi: 10.1186/s12889-021-10427-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-021-10427-2</ArticleId><ArticleId IdType="pmc">PMC7948667</ArticleId><ArticleId IdType="pubmed">33706738</ArticleId></ArticleIdList></Reference><Reference><Citation>Holm M, Hartling UB, Schmidt LS, Glenth&#xf8;j JP, Kruse A, Rytter MH, et al. Multisystem inflammatory syndrome in children occurred in one of four thousand children with severe acute respiratory syndrome coronavirus 2. Acta Paediatr. 2021;110(9):2581&#x2013;2583. doi: 10.1111/apa.15985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apa.15985</ArticleId><ArticleId IdType="pmc">PMC8444758</ArticleId><ArticleId IdType="pubmed">34129731</ArticleId></ArticleIdList></Reference><Reference><Citation>Whittaker E, Bamford A, Kenny J, Kaforou M, Jones CE, Shah P, et al. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA. 2020;324(3):259&#x2013;269. doi: 10.1001/jama.2020.10369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.10369</ArticleId><ArticleId IdType="pmc">PMC7281356</ArticleId><ArticleId IdType="pubmed">32511692</ArticleId></ArticleIdList></Reference><Reference><Citation>Holm M, Espenhain L, Glenth&#xf8;j J, Schmidt LS, Nordly SB, Hartling UB, et al. Risk and phenotype of multisystem inflammatory syndrome in vaccinated and unvaccinated Danish children before and during the Omicron wave. JAMA Pediatr. 2022;176(8):821&#x2013;823. doi: 10.1001/jamapediatrics.2022.2206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapediatrics.2022.2206</ArticleId><ArticleId IdType="pmc">PMC9178498</ArticleId><ArticleId IdType="pubmed">35675054</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen JM, Carter MJ, Cheung CR, Ladhani S, Group ftEPIMSTrtS-C-S. Lower risk of multisystem inflammatory syndrome in children with the delta and Omicron variants of severe acute respiratory syndrome coronavirus 2. Clinical Infectious Diseases. 2022;76(3):e518-e21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9278259</ArticleId><ArticleId IdType="pubmed">35788276</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephenson T, Pinto Pereira SM, Shafran R, de Stavola BL, Rojas N, McOwat K, et al. Physical and mental health 3 months after SARS-CoV-2 infection (long COVID) among adolescents in England (CLoCk): a national matched cohort study. The Lancet Child &amp; Adolescent Health. 2022;6(4):230&#x2013;239. doi: 10.1016/S2352-4642(22)00022-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-4642(22)00022-0</ArticleId><ArticleId IdType="pmc">PMC8820961</ArticleId><ArticleId IdType="pubmed">35143770</ArticleId></ArticleIdList></Reference><Reference><Citation>Selvakumar J, Havdal L, Drevvatne M, Brodwall EM, Lund Berven L, Stiansen-Sonerud T, et al. Prevalence and characteristics associated with post&#x2013;COVID-19 condition among nonhospitalized adolescents and young adults. JAMA Network Open. 2023;6(3):e235763. doi: 10.1001/jamanetworkopen.2023.5763.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.5763</ArticleId><ArticleId IdType="pmc">PMC10064252</ArticleId><ArticleId IdType="pubmed">36995712</ArticleId></ArticleIdList></Reference><Reference><Citation>Office for National Statistics. New-onset, self-reported long COVID after coronavirus (COVID-19) reinfection in the UK: 23 February 2023 2023 [Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/newonsetselfreportedlongcovidaftercoronaviruscovid19reinfectionintheuk/23february2023.</Citation></Reference><Reference><Citation>Shah ASV, Gribben C, Bishop J, Hanlon P, Caldwell D, Wood R, et al. Effect of vaccination on transmission of SARS-CoV-2. N Engl J Med. 2021;385(18):1718&#x2013;1720. doi: 10.1056/NEJMc2106757.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2106757</ArticleId><ArticleId IdType="pmc">PMC8451182</ArticleId><ArticleId IdType="pubmed">34496200</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyngse FP, Mortensen LH, Denwood MJ, Christiansen LE, M&#xf8;ller CH, Skov RL, et al. Household transmission of the SARS-CoV-2 Omicron variant in Denmark. Nat Commun. 2022;13(1):5573. doi: 10.1038/s41467-022-33328-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-33328-3</ArticleId><ArticleId IdType="pmc">PMC9508106</ArticleId><ArticleId IdType="pubmed">36151099</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter EB, Talaat KR, Sabharwal C, Gurtman A, Lockhart S, Paulsen GC, et al. Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age. N Engl J Med. 2021;386(1):35&#x2013;46. doi: 10.1056/NEJMoa2116298.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116298</ArticleId><ArticleId IdType="pmc">PMC8609605</ArticleId><ArticleId IdType="pubmed">34752019</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu&#xf1;oz FM, Sher LD, Sabharwal C, Gurtman A, Xu X, Kitchin N, et al. Evaluation of BNT162b2 Covid-19 vaccine in children younger than 5 years of age. N Engl J Med. 2023;388(7):621&#x2013;634. doi: 10.1056/NEJMoa2211031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2211031</ArticleId><ArticleId IdType="pmc">PMC9947923</ArticleId><ArticleId IdType="pubmed">36791162</ArticleId></ArticleIdList></Reference><Reference><Citation>Frenck RW, Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N Engl J Med. 2021;385(3):239&#x2013;250. doi: 10.1056/NEJMoa2107456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2107456</ArticleId><ArticleId IdType="pmc">PMC8174030</ArticleId><ArticleId IdType="pubmed">34043894</ArticleId></ArticleIdList></Reference><Reference><Citation>Creech CB, Anderson E, Berthaud V, Yildirim I, Atz AM, Melendez Baez I, et al. Evaluation of mRNA-1273 Covid-19 vaccine in children 6 to 11 years of age. N Engl J Med. 2022;386(21):2011&#x2013;2023. doi: 10.1056/NEJMoa2203315.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2203315</ArticleId><ArticleId IdType="pmc">PMC9127699</ArticleId><ArticleId IdType="pubmed">35544369</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemaitelly H, AlMukdad S, Ayoub HH, Altarawneh HN, Coyle P, Tang P, et al. Covid-19 vaccine protection among children and adolescents in Qatar. N Engl J Med. 2022;387(20):1865&#x2013;1876. doi: 10.1056/NEJMoa2210058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2210058</ArticleId><ArticleId IdType="pmc">PMC9644642</ArticleId><ArticleId IdType="pubmed">36322837</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin DY, Xu Y, Gu Y, Zeng D, Wheeler B, Young H, et al (2023) Effects of COVID-19 vaccination and previous SARS-CoV-2 infection on omicron infection and severe outcomes in children under 12 years of age in the USA: an observational cohort study. Lancet Infect Dis.&#xa0;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10275621</ArticleId><ArticleId IdType="pubmed">37336222</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali K, Berman G, Zhou H, Deng W, Faughnan V, Coronado-Voges M, et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. N Engl J Med. 2021;385(24):2241&#x2013;2251. doi: 10.1056/NEJMoa2109522.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2109522</ArticleId><ArticleId IdType="pmc">PMC8385554</ArticleId><ArticleId IdType="pubmed">34379915</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai FTT, Chan EWW, Huang L, Cheung CL, Chui CSL, Li X, et al. Prognosis of myocarditis developing after mRNA COVID-19 vaccination compared with viral myocarditis. J Am Coll Cardiol. 2022;80(24):2255&#x2013;2265. doi: 10.1016/j.jacc.2022.09.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2022.09.049</ArticleId><ArticleId IdType="pmc">PMC9721305</ArticleId><ArticleId IdType="pubmed">36480967</ArticleId></ArticleIdList></Reference><Reference><Citation>Kracalik I, Oster ME, Broder KR, Cortese MM, Glover M, Shields K, et al. Outcomes at least 90 days since onset of myocarditis after mRNA COVID-19 vaccination in adolescents and young adults in the USA: a follow-up surveillance study. Lancet Child Adolesc Health. 2022;6(11):788&#x2013;798. doi: 10.1016/S2352-4642(22)00244-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-4642(22)00244-9</ArticleId><ArticleId IdType="pmc">PMC9555956</ArticleId><ArticleId IdType="pubmed">36152650</ArticleId></ArticleIdList></Reference><Reference><Citation>Goddard K, Hanson KE, Lewis N, Weintraub E, Fireman B, Klein NP. Incidence of myocarditis/pericarditis following mRNA COVID-19 vaccination among children and younger adults in the United States. Ann Intern Med. 2022;175(12):1169&#x2013;1771. doi: 10.7326/M22-2274.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M22-2274</ArticleId><ArticleId IdType="pmc">PMC9578536</ArticleId><ArticleId IdType="pubmed">36191323</ArticleId></ArticleIdList></Reference><Reference><Citation>Naveed Z, Li J, Spencer M, Wilton J, Naus M, Garc&#xed;a HAV, et al. Observed versus expected rates of myocarditis after SARS-CoV-2 vaccination: a population-based cohort study. Can Med Assoc J. 2022;194(45):E1529&#x2013;E1536. doi: 10.1503/cmaj.220676.</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/cmaj.220676</ArticleId><ArticleId IdType="pmc">PMC9828950</ArticleId><ArticleId IdType="pubmed">36410749</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchan SA, Seo CY, Johnson C, Alley S, Kwong JC, Nasreen S, et al. Epidemiology of myocarditis and pericarditis following mRNA vaccination by vaccine product, schedule, and interdose interval among adolescents and adults in Ontario, Canada. JAMA Network Open. 2022;5(6):e2218505. doi: 10.1001/jamanetworkopen.2022.18505.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.18505</ArticleId><ArticleId IdType="pmc">PMC9233237</ArticleId><ArticleId IdType="pubmed">35749115</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe A, Kani R, Iwagami M, Takagi H, Yasuhara J, Kuno T. Assessment of efficacy and safety of mRNA COVID-19 vaccines in children aged 5 to 11 years: a systematic review and meta-analysis. JAMA Pediatr. 2023;177(4):384&#x2013;394. doi: 10.1001/jamapediatrics.2022.6243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapediatrics.2022.6243</ArticleId><ArticleId IdType="pmc">PMC9871947</ArticleId><ArticleId IdType="pubmed">36689319</ArticleId></ArticleIdList></Reference><Reference><Citation>Colman E, Puspitarani GA, Enright J, Kao RR. Ascertainment rate of SARS-CoV-2 infections from healthcare and community testing in the UK. J Theor Biol. 2023;558:111333. doi: 10.1016/j.jtbi.2022.111333.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtbi.2022.111333</ArticleId><ArticleId IdType="pmc">PMC9636607</ArticleId><ArticleId IdType="pubmed">36347306</ArticleId></ArticleIdList></Reference><Reference><Citation>Munyangaju I, L&#xf3;pez-Varela E, Bassat Q. Closing the gap in childhood immunisation after the pandemic. BMJ. 2023;380:p627. doi: 10.1136/bmj.p627.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.p627</ArticleId><ArticleId IdType="pubmed">36944436</ArticleId></ArticleIdList></Reference><Reference><Citation>Officefor National Statistics. Coronavirus (COVID-19) latest insights: vaccines 2023 [Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19latestinsights/vaccines#vaccine-uptake-by-demographic.</Citation></Reference><Reference><Citation>Bundesministerium fur Gesundheit. Current Vaccination Status 2023 [Available from: https://impfdashboard.de/en/.</Citation></Reference><Reference><Citation>Our World In Data. Coronavirus (COVID-19) vaccinations 2023 [Available from: https://ourworldindata.org/covid-vaccinations.</Citation></Reference><Reference><Citation>UK Health Security Agency. COVID-19: the green book, chapter 14a 2023&#xa0;</Citation></Reference><Reference><Citation>Br&#xfc;ssow H. COVID-19: Omicron &#x2013; the latest, the least virulent, but probably not the last variant of concern of SARS-CoV-2. Microb Biotechnol. 2022;15(7):1927&#x2013;1939. doi: 10.1111/1751-7915.14064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1751-7915.14064</ArticleId><ArticleId IdType="pmc">PMC9111164</ArticleId><ArticleId IdType="pubmed">35443078</ArticleId></ArticleIdList></Reference><Reference><Citation>Joint Committee on Vaccination and Immunisation. JCVI statement on COVID-19 vaccination of children and young people aged 12 to 17 years: 15 July 2021 2021 [Available from: https://www.gov.uk/government/publications/covid-19-vaccination-of-children-and-young-people-aged-12-to-17-years-jcvi-statement/jvci-statement-on-covid-19-vaccination-of-children-and-young-people-aged-12-to-17-years-15-july-2021.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>